Induction of antioxidants by adriamycin in mouse heart

Biochemical Pharmacology

Volumn 56, Issue 1, 1998, Pages 87-93

  Yin, Xianhua ^a   Wu, Huiyun ^a   Chen, Yan ^a   Kang, Y James ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

glutamylcysteine synthetase; Adriamycin; Catalase; Glutathione; Glutathione peroxidase; Metallothionein; mRNA; Superoxide dismutase

Indexed keywords

ANTIOXIDANT; COPPER ZINC SUPEROXIDE DISMUTASE; DOXORUBICIN; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; METALLOTHIONEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; DOXORUBICIN; GENE EXPRESSION REGULATION; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE PEROXIDASE; METALLOTHIONEIN; MICE; MYOCARDIUM; RNA, MESSENGER; SUPEROXIDE DISMUTASE;

EID: 0031783516     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00099-9     Document Type: Article

References (48)

1. Blum RH and Carter SK, Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80: 249-259, 1974.
2. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M and Muggia FM, Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717, 1979.
3. Keizer HG, Pindedo HM, Schuurhuis GJ and Joenje H, Doxorubicin (Adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47: 219-231, 1990.
4. Lee V, Randhawa AK and Singal PK, Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am J Physiol 261: H989-H995, 1991.
5. Doroshow JH, Locker GY and Myers CE, Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest 65: 128-135, 1980.
6. Thornalley PJ and Dodd NJ, Free radical production from normal and adriamycin-treated rat cardiac sarcosomes. Biochem Pharmacol 34: 669-674, 1985.
7. Odom AL, Hatwig CA, Stanley JS and Benson AM, Biochemical determinants of Adriamycin® toxicity in mouse liver, heart and intestine. Biochem Pharmacol 43: 831-836, 1992.
8. Bachur NR, Gordon SL and Gee MW, A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38: 1745-1750, 1978.
9. Kalyanaraman B, Sealy RC and Sinha BK, An electron spin resonance study of the reduction of peroxides by anthracycline semiquinones. Biochim Biophys Acta 779: 270-275, 1984.
10. Revis NW and Marusic N, Glutathione peroxidase activity and selenium concentration in the hearts of doxorubicin-treated rabbits. J Mol Cell Cardiol 10: 945-951, 1978.
11. Julicher RH, Sterrenberg L, Bast A, Riksen RO, Koomen JM and Noordhoek J, The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart. J Pharm Pharmacol 38: 277-282, 1986.
12. Sazuka Y, Tanizawa H and Takino Y, Effect of adriamycin on the activities of superoxide dismutase, glutathione peroxidase and catalase in tissues of mice. Jpn J Cancer Res 80: 89-94, 1989.
13. Fialkoff H, Goodman MF and Seraydarian MW, Differential effect of Adriamycin on DNA replicative and repair synthesis in cultured neonatal rat cardiac cells. Cancer Res 39: 1321-1327, 1979.
14. Formelli F, Zedeck MS, Sternberg SS and Philips FS, Effects of Adriamycin on DNA synthesis in mouse and rat heart. Cancer Res 38: 3286-3292, 1978.
15. Sazuka Y, Tanizawa H and Takino Y, Effect of adriamycin on DNA, RNA and protein biosyntheses in mouse tissues, in connection with its cardiotoxicity. Jpn J Cancer Res 80: 1000-1005, 1989.
16. Van Helden PD and Wiild IJ, Effects of adriamycin on heart and skeletal muscle chromatin. Biochem Pharmacol 31: 973-977, 1982.
17. Bagchi D, Bagchi M, Hassoun EA, Kelly J and Stohs SJ, Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology 95: 1-9, 1995.
18. Kang YJ, Chen Y and Epstein PN, Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 271: 12610-12616, 1996.
19. Church GM and Gilbert W, Genomic sequencing. Proc Natl Acad Sci USA 81: 1991-1995, 1984.
20. Nebot C, Moutet M, Huet P, Xu JZ, Yadan JC and Chaudiere J, Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol. Anal Biochem 214: 442-451, 1993.
21. Aebi H, Catalase in vitro. Methods Enzymol 105: 121-126, 1984.
22. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Proverzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klerk DC, Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985.
23. Flohé F and Günzler WA, Assays of glutathione peroxidase. Methods Enzymol 105: 114-121, 1984.
24. Carlberg I and Mannervik B, Glutathione reductase. Methods Enzymol 113: 484-490, 1985.
25. Seelig GF and Meister A, Glutathione biosynthesis; γ-Glutamylcysteine synthetase from rat kidney. Methods Enzymol 113: 379-390, 1985.
26. Tietze F, Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Application to mammalian blood and other tissues. Anal Biochem 57: 502-522, 1969.
27. Eaton DL and Cherian MG, Determination of metallothionein in tissue by cadmium-hemoglobin affinity assay. Methods Enzymol 205: 83-88, 1991.
28. Dalbow DG and Jaenke RS, In vivo RNA synthesis in the hearts of Adriamycin-treated rats. Cancer Res 42: 79-83, 1982.
29. Zähringer J, Höfling B, Raum W and Kandolph R, Effect of adriamycin on the polyribosome and messenger-RN A content of rat heart muscle. Biochim Biophys Acta 608: 315-323, 1980.
30. Zähringer J, Kandolf R and Raum W, Decrease of myocardial mRNA in adriamycin-treated rats. FEBS Lett 123: 169-172, 1981.
31. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L and Torti FM, Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 87: 4275-4279, 1990.
32. Papoian T and Lewis W, Adriamycin cardiotoxicity in vivo. Selective alterations in rat cardiac mRNA. Am J Pathol 136: 1201-1207, 1990.
33. Papoian T and Lewis W, Selective alterations in rat cardiac mRNA induced by doxorubicin: Possible subcellular mechanisms. Exp Mol Pathol 54: 112-121, 1991.
34. Dalton T, Palmiter RD and Andrews GK, Transcriptional induction of the mouse metallothionein-I gene in hydrogen peroxide-treated HeLa cells involves a composite major late transcription factor/antioxidant response element and metal response promoter elements. Nucleic Acids Res 22: 5016-5023, 1994.
35. Durnam DM and Palmiter RD, Transcriptional regulation of the mouse metallothionein-I gene by heavy metals. J Biol Chem 256: 5712-5716, 1981.
36. 2+-induced synthesis of metallothionein in HeLa cells. Biochem J 227: 879-886, 1985.
37. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K and Young RC, Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197: 165-167, 1977.
38. Yoda Y, Nakazawa M, Abe T and Kawakami Z, Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione. Cancer Res 46: 2551-2556, 1986.
39. Olson RD, MacDonald JS, vanBoxtel CJ, Boerth RC, Harbison RD, Slonim AE, Freeman RW and Oates JA, Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of Adriamycin. J Pharmacol Exp Ther 215: 450-454, 1980.
40. Gustafson DL, Swanson JD and Pritsos CA, Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following doxorubicin therapy. Free Radic Res Commun 19: 111-120, 1993.
41. D'Alessandro N, Dusonchet L, Crosta L, Crescimanno M and Rausa L, Does catalase play a role in Adriamycin induced cardiotoxicity? Pharmacol Res Commun 12: 441-446, 1980.
42. D'Alessandro N, Candiloro V, Crescimanno M, Flandina C, Dusonchet L, Crosta L and Rausa L, Effects of multiple doxorubicin doses on mouse cardiac and hepatic catalase. Pharmacol Res Commun 16: 145-151, 1984.
43. Sato M and Bremner I, Oxygen free radicals and metallothionein. Free Radic Biol Med 14: 325-337, 1993.
44. Hidalgo J, Campmany L, Borras M, Garvey JS and Armario A, Metallothionein response in rats: Role in free radical scavenging. Am J Physiol 255: E518-E524, 1988.
45. Bauman JW, Liu J, Liu YP and Klaassen CD, Increase in metallothionein produced by chemicals that induce oxidative stress. Toxicol Appl Pharmacol 110: 347-354, 1991.
46. Satoh M, Naganuma A and Imura N, Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination. Cancer Chemother Pharmacol 21: 176-178, 1988.
47. Naganuma A, Satoh M and Imura N, Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice. Jpn J Cancer Res 79: 406-411, 1988.
48. Kang YJ, Chen Y, Yu A, Voss-McCowan M and Epstein PN, Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100: 1501-1506, 1997.